However, it still remains ill-defined whether serum miR-222-3p can serve as a potential biomarker for predicting the response to NAT in HER2-positive breast cancer patients as well as their trastuzumab-induced cardiotoxicity. This evidence concerns the gene ERBB2 and breast cancer.